| OCUGEN INC. DL-,001 |
| USA |
| Gesundheit |
| US67577C1053 / A2PSZH |
| 2H51 (Frankfurt) / OCGN (NASDAQ) |
| FRA:2H51, ETR:2H51, 2H51:GR, NASDAQ:OCGN |
| - |
| https://ocugen.com/ |
|
Ocugen Inc. is a biopharmaceutical company headquartered in Malvern, Pennsylvania, specializing in the discovery, development, and commercialization of gene therapies, cell therapies, and vaccines. The company's primary focus centers on rare inherite..
>Volltext.. |
| 390.96 Mio. EUR |
| 392.21 Mio. EUR |
| 3.85 Mio. EUR |
| -55.32 Mio. EUR |
| -61.77 Mio. EUR |
| -0.2 EUR |
| 28.7 Mio. EUR |
| 27.45 Mio. EUR |
| - |
| 1.54 |
| -7.54% |
| -16.76% |
| - |
| - |
| - |
| - |
| OCUGEN |
| 25.05.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|